Genentech: Hans Erickson | Senior Scientist/ Director, Department of Protein Chemistry

A link to this page has been copied to your clipboard.

http://www.gene.com/scientists/our-scientists/hans-erickson

Paste this link in an email to share.

Ok

Scientists / Our Scientists

"It is an amazing privilege to work with such talented and creative researchers across Genentech to advance meaningful therapies for patients."

Years at Genentech

Publications

Awards & Honors

Motivated by Genentech’s focus on patients and scientific excellence, I joined the Department of Protein Chemistry in 2014 after working for eleven years developing antibody-drug conjugates at ImmunoGen.

The Department of Protein Chemistry utilizes recombinant protein and bioconjugation expertise to design and produce novel therapeutic candidates for the treatment of diseases with high unmet clinical need.

Featured Publication

Attachment Site Cysteine Thiol pKa Is a Key Driver for Site-Dependent Stability of THIOMAB Antibody-Drug Conjugates.

Bioconjug Chem. 2017 Oct 18;28(10):2538-2548.

Vollmar BS, Wei B, Ohri R, Zhou J, He J, Yu SF, Leipold D, Cosino E, Yee S, Fourie-O'Donohue A, Li G, Phillips GL, Kozak KR, Kamath A, Xu K, Lee G, Lazar GA, Erickson HK.

View Abstract

My primary role is to direct the activities of the Department of Protein Chemistry. My research lab is focused on understanding the key biological mechanisms associated with our leading therapeutic candidates in Molecular Oncology. We collaborate closely with colleagues across the research community in this pursuit. Recently, we explored how the selection of the mutation sites impacts the stability of cysteine-engineered antibody-drug conjugates.

Our current interests are focused on deepening our mechanistic understanding of T cell-directed therapies using biochemical and biophysical approaches.

Attachment Site Cysteine Thiol pKa Is a Key Driver for Site-Dependent Stability of THIOMAB Antibody-Drug Conjugates

Bioconjugate Chemistry, ISSN: 15204812 10431802

Breanna S. Vollmar; Binqing Wei; Rachana Ohri; Jianhui Zhou; Jintang He; Shang-Fan Yu; Douglas Leipold; Ely Cosino; Sharon Yee; Aimee Fourie-O'Donohue; Ginny (Guangmin) Li; Gail Phillips; Kathy Kozak; Amrita Kamath; Keyang Xu; Genee Lee; Greg A. Lazar; Hans Erickson

View on Scopus

Antibody drug conjugates differentiate uptake and DNA alkylation of pyrrolobenzodiazepines in tumors from organs of xenograft mice

Drug Metabolism and Disposition, ISSN: 1521009X

Yong Ma; Cyrus Khojasteh; Marcel Hop; Hans Erickson; Andy Polson; Thomas Pillow; Shang-Fan Yu; Hong Wang; Peter Dragovich; Donglu Zhang

View on Scopus

Chemical structure and concentration of intratumor catabolites determine efficacy of antibody drug conjugates

Drug Metabolism and Disposition, ISSN: 1521009X

Donglu Zhang; Shang-Fan Yu; Yong Ma; Keyang Xu; Peter Dragovich; Thomas Pillow; Luna Liu; Geoff Del Rosario; Jintang He; Zhonghua Pei; Jack Sadowsky; Hans Erickson; Marcel Hop; Cyrus Khojasteh

View on Scopus

Microscale screening of antibody libraries as maytansinoid antibody-drug conjugates

mAbs, ISSN: 19420870

Kalli C. Catcott; Molly A. McShea; Carl Uli Bialucha; Kathy L. Miller; Stuart W. Hicks; Parmita Saxena; Thomas G. Gesner; Mikias Woldegiorgis; Megan E. Lewis; Chen Bai; Michael S. Fleming; Seth A. Ettenberg; Hans Erickson; Nicholas C. Yoder

View on Scopus

Design of coltuximab ravtansine, a CD19-targeting antibody-drug conjugate (ADC) for the treatment of B-cell malignancies: Structure-activity relationships and preclinical evaluation

Molecular Pharmaceutics, ISSN: 15438392

E. Erica Hong; Hans Erickson; Robert J. Lutz; Kathleen R. Whiteman; Gregory Jones; Yelena Kovtun; Veronique Blanc; John M. Lambert

View on Scopus

Mechanistic pharmacokinetic/pharmacodynamic modeling of in vivo tumor uptake, catabolism, and tumor response of trastuzumab maytansinoid conjugates

Cancer Chemotherapy and Pharmacology, ISSN: 14320843 03445704

Russ Wada; Hans Erickson; Gail Phillips; Carmela A. Provenzano; Douglas Leipold; Elaine Mai; Holly A. Johnson; Jack (Jay) Tibbitts

View on Scopus

American Association of Pharmaceutical Scientists National Biotechnology Conference short course: Translational challenges in developing antibody-drug conjugates

mAbs, ISSN: 19420862

Karen Thudium; Sanela Bilic; Douglas Leipold; Bill Mallet; Surinder Kaur; Bernd Meibohm; Hans Erickson; Jack (Jay) Tibbitts; Hong Zhao; Manish Gupta

View on Scopus

The effect of different linkers on target cell catabolism and pharmacokinetics/pharmacodynamics of trastuzumab maytansinoid conjugates

Molecular Cancer Therapeutics, ISSN: 15357163

Hans Erickson; Gail Phillips; Douglas Leipold; Carmela A. Provenzano; Elaine Mai; Holly A. Johnson; Bert Gunter; Charlene A. Audette; Manish Gupta; Jan Pinkas; Jack (Jay) Tibbitts

View on Scopus

University of California, San Diego , PhD – 1999
University of California, Santa Barbara, B.S. Chemistry – 1994

NIH Postdoctoral Fellow, University of Utah – 2000-2003

Attention: This page may not render properly. The browser you are using, Internet Explorer 10, is no longer supported.

A link to this page has been copied to your clipboard.

Hans Erickson

Senior Scientist/ Director, Department of Protein Chemistry

Featured Publication

Attachment Site Cysteine Thiol pKa Is a Key Driver for Site-Dependent Stability of THIOMAB Antibody-Drug Conjugates.